A binuclear aluminium complex as a single competent catalyst for efficient synthesis of urea, biuret, isourea, isothiourea, phosphorylguanidine, and quinazolinones.

The synthesis and characterisation of two mononuclear aluminium alkyl complexes with the general composition [Al(Me)2{Ph2P(E)N(CH2)2N(CH2CH2)2O}] (E = Se (2a); S (2b)), and two binuclear aluminium complexes, [Al(Me)2{Ph2P-(E)N(CH2)2N(CH2CH2)2O}(AlMe3)] (E = Se (3a) and S (3b)), are described. The binuclear aluminium alkyl complex 3a proved to be a proficient catalyst for the addition of simple nucleophiles to heterocumulenes, leading to the synthesis of a variety of products such as urea, biuret, isourea, isothiourea, phosphorylguanidine, and quinazolinone derivatives, in contrast to its mononuclear analogues. Complex 3a is the first example of a single competent catalyst, which is also low-cost and eco-friendly and derived from a main-group metal, under solvent-free conditions either at room temperature or mild temperatures. Complex 3a possessed a wide functional group tolerance including heteroatoms, yielding the corresponding insertion products in good quantities and with high selectivity.

Disseminated Mycobacterium tuberculosis: An Unusual Presentation with Associated Hemophagocytic Lymphohistiocytosis.

Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal, and systemic hyperinflammatory syndrome with exacerbated and uncontrolled activation of histiocytes and lymphocytes against mature cells. Secondary HLH can occur in association with a myriad of underlying infections or malignancies. Our patient is a 38-year-old male prisoner with poorly controlled diabetes and no known other medical conditions. He was referred to our emergency department with three-week history of worsening malaise, weight loss, fever, bruising, and shortness of breath; imaging showed pneumomediastinum, lung nodule, and adrenal mass. Biopsy of the lung nodule revealed acid-fast bacilli. Furthermore, bone marrow biopsy showed foci of necrosis with associated acid-fast bacilli and hemophagocytosis highlighted by CD163 stain; consequently, secondary HLH was suggested. Hence, lab results were reviewed and found to satisfy five of the eight secondary HLH criteria. Moreover, ferritin was >10,000 ng/ml, which has been suggested to be highly suspicious for HLH. The patient was started on anti-MAC therapy. Unfortunately, the patient's status declined rapidly; he developed multi-organ failure and succumbed to disease. Later, his culture confirmed Mycobacterium tuberculosis. In conclusion, we presented a rare and challenging case of secondary HLH associated with disseminated Mycobacterium tuberculosis. A high index of suspicion is required for early diagnosis and treatment, and pathologists should be aware of Mycobacterium tuberculosis' association with secondary HLH.

Highly Chemoselective Hydroboration of Alkynes and Nitriles Catalyzed by Group 4 Metal Amidophosphine-Borane Complexes.

We report a series of titanium and zirconium complexes supported by dianionic amidophosphine-borane ligands, synthesized by amine elimination and salt metathesis reactions. The TiIV complex [{Ph2P(BH3)N}2C6H4Ti(NMe2)2] (1) was obtained by the reaction between tetrakis-(dimethylamido)titanium(IV) and the protic aminophosphine-borane ligand [{Ph2P(BH3)NH}2C6H4] (LH2) at ambient temperature. Both the heteroleptic zirconium complexes-[η5-(C5H5)2Zr{Ph2P(BH3)N}2C6H4] (2) and [[{Ph2P(BH3)N}2C6H4]ZrCl2] (3)-and the homoleptic zirconium complex [[{Ph2P(BH3)N}2C6H4]2Zr] (4) were obtained in good yield by the salt metathesis reaction of either zirconocene dichloride [η5-(C5H5)2ZrCl2] or zirconium tetrachloride with the dilithium salt of the ligand [{Ph2P(BH3)NLi}2C6H4] (LLi2), which was prepared in situ. The molecular structures of the complexes 1, 2, and 4 in their solid states were confirmed by single-crystal X-ray diffraction analysis. Of these complexes, only titanium complex 1 acts as an effective catalyst for the facile hydroboration of terminal alkynes, yielding exclusive E-isomers. The hydroboration of organic nitriles yielded diborylamines with a broad substrate scope, including broad functional group compatibility. The mechanism of hydroboration occurs through the formation of titanium hydride as an active species.

CAR-T treatment for hematological malignancies.

Chimeric antigen receptor (CAR)-T-cell therapy has sparked a wave of optimism in hematological malignancies, reflected by the successful results of early clinical trials involving patients with pre-B-cell acute lymphoblastic leukemia, B-cell lymphomas and multiple myeloma. CAR-T-cell therapy is considered to be a novel immunotherapy treatment that has the potential for curing certain hematological cancers. However, as use of CAR-T-cell therapy has grown, new challenges have surfaced. These challenges include the process of manufacturing the CAR-T cells, the mechanisms of resistance that underlie disease relapse, adverse effects and cost. This review describes the published results of clinical trials and expected developments to overcome CAR-T resistance.